COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference26/09/2025
-   
  ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic26/09/2025
-   
  Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock26/09/2025
-   
  Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol26/09/2025
-   
  Sanuwave Announces Strategic Debt Refinancing with New Credit Facility26/09/2025
-   
  Harrow to Acquire Melt Pharmaceuticals26/09/2025
-   
  Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation26/09/2025
-   
  ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic26/09/2025
-   
  RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 202526/09/2025
-   
  Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide26/09/2025
-   
  BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented26/09/2025
-   
  Concept Life Sciences Expands Integrated Drug Discovery Facilities26/09/2025
-   
  Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care26/09/2025
-   
  Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics26/09/2025
-   
  Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs26/09/2025
-   
  Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 202526/09/2025
-   
  Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 202526/09/2025
-   
  OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy26/09/2025
-   
  OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie26/09/2025
Pages